Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Cross-cultural Adaptation, Reliability, and Validity of the BICAMS in Brazil.
IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.
Mitoxantrone-induced suicidal erythrocyte death.
Food and Drug Administration drug insert for Campath (alemtuzumab)
A meta-analysis of whole genome linkage screens in multiple sclerosis.
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis.
Fingolimod is a potential novel therapy for multiple sclerosis.
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status
The Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis.
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b)
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis.
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
Immunology 2014
Teaching NeuroImages: MRI in advanced neuromyelitis optica.
CHMP adopts positive opinion for PLEGRIDY™ (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union
Laquinimod Phase IIa Study in Active Crohn's Disease
FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons.
Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review.
Gustatory Dysfunction in Multiple Sclerosis
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

Pages